17BIPHE2——一种低蛋白酶敏感性工程化cathelicidin抗菌肽——是有效的杀精剂及抗淋病奈瑟菌微生物剂
本研究在体外比较工程化cathelicidin抗菌肽17BIPHE2与亲本肽LL-37、GF-17在含宫颈阴道液(CVF)培养基中对人精子的杀精活性,并在小鼠评估体内避孕效果及可逆性,同时测定其对淋病奈瑟菌的杀菌作用。结果显示相同质量浓度下17BIPHE2杀精活性最高,杀精浓度为32.4 µM,主要因其对CVF蛋白酶敏感性较低;小鼠三次处理后生殖道正常且生育力恢复。
要点
- 相同质量浓度下,17BIPHE2对含CVF培养基中人精子的杀精活性高于LL-37和GF-17,杀精浓度为32.4 µM。
- 17BIPHE2杀精活性较高主要因其对CVF蛋白酶敏感性较低。
- 小鼠经32.4 µM 17BIPHE2处理三次后生殖道正常,停止处理后生育力恢复。
核心结论
- 相同质量浓度下,17BIPHE2对含CVF培养基中人精子的杀精活性最高,主要因其对CVF蛋白酶敏感性较低。
- 17BIPHE2在其杀精浓度下对淋病奈瑟菌也有杀菌活性,是有望开发为阴道多用途预防技术制剂的候选物。
研究设计与样本
- 体外研究:在小鼠和人精子(均重悬于培养基)中评估17BIPHE2杀精活性,随后在含CVF培养基中孵育的人精子上比较17BIPHE2与LL-37、GF-17的杀精活性及肽稳定性。
- 体内研究:在小鼠评估17BIPHE2的避孕效果及其可逆性。
- 体外研究:测定17BIPHE2对淋病奈瑟菌的杀菌效果。
主要发现
- 相同质量浓度下,17BIPHE2对含CVF培养基中人精子的杀精活性高于LL-37和GF-17,杀精浓度为32.4 µM。
- 17BIPHE2杀精活性较高主要归因于其对CVF蛋白酶的敏感性较低。
- 经32.4 µM 17BIPHE2处理三次的小鼠雌性生殖道保持正常,停止处理后生育力恢复。
- 17BIPHE2在其杀精浓度下对淋病奈瑟菌具有杀菌活性。
关键数值与推荐
- 17BIPHE2对含CVF培养基中人精子的杀精浓度为32.4 µM。
- 小鼠经32.4 µM 17BIPHE2处理三次,生殖道正常,停止处理后生育力恢复。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 出于伦理原因,目前无法在女性中开展17BIPHE2对受精和妊娠的抑制作用研究。
- 研究虽已证明17BIPHE2在体外对小鼠和人精子具有杀精效果,但仍需开发17BIPHE2的剂型(如水凝胶),以使其留在阴道/子宫腔内控释发挥杀精作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is 17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, a better spermicide in cervicovaginal fluid (CVF) than its parental peptides, LL-37 and GF-17? SUMMARY ANSWER: At the same mass concentration, 17BIPHE2 exhibited the highest spermicidal activity on human sperm resuspended in CVF-containing medium. WHAT IS KNOWN ALREADY: LL-37 and its truncated peptide GF-17 exert both spermicidal and microbicidal activities, although they are prone to proteolytic degradation in body fluids. STUDY DESIGN, SIZE, DURATION: Spermicidal activities of 17BIPHE2 were evaluated in vitro in mouse and human sperm, both resuspended in medium, and then on human sperm incubated in CVF-containing medium; in the latter condition, the spermicidal activity and peptide stability in CVF of 17BIPHE2 were compared with that of LL-37 and GF-17. The in vivo contraceptive effects of 17BIPHE2 and the reversibility thereof were then assessed in mice. Finally, in vitro microbicidal effects of 17BIPHE2 on Neisseria gonorrhoeae were determined. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sperm motility and plasma membrane integrity were assessed by videomicroscopy and exclusion of Sytox Green, a membrane-impermeable fluorescent dye, respectively. Successful in vitro fertilization (IVF) was determined by the presence of two pronuclei in oocytes following their coincubation with capacitated untreated or 17BIPHE2-treated sperm. Sperm alone or with 17BIPHE2 were transcervically injected into female mice and successful in vivo fertilization was indicated by the formation of two-cell embryos 42-h postinjection, and by pregnancy through pup delivery 21-25 days afterwards. Peptide intactness was assessed by immunoblotting and HPLC. Reversibility of the contraceptive effects of 17BIPHE2 was evaluated by resumption of pregnancy of the female mice, pretranscervically injected with 17BIPHE2, following natural mating with fertile males. Minimum inhibitory/bactericidal concentrations of 17BIPHE2 on N. gonorrhoeae were obtained through microdilution broth assay. MAIN RESULTS AND THE ROLE OF CHANCE: At the same mass concentration, 17BIPHE2 was a more effective spermicide than LL-37 or GF-17 on human sperm resuspended in CVF-containing medium, with the spermicidal concentration of 32.4 µM. This was mainly due to lower susceptibility of 17BIPHE2 to CVF proteases. Importantly, the reproductive tract of mouse females treated three times with 32.4 µM 17BIPHE2 remained normal and their fecundity resumed after stopping 17BIPHE2 treatment. LIMITATIONS, REASONS FOR CAUTION: For ethical reasons, the inhibitory effects of 17BIPHE2 on fertilization and pregnancy cannot presently be performed in women. Also, while our study has proven the effectiveness of 17BIPHE2 as a spermicide for mouse and human sperm in vitro, dosage formulation (e.g. in hydrogel) of 17BIPHE2 still needs to be developed to allow 17BIPHE2 to remain in the vagina/uterine cavity with controlled release for its spermicidal action. WIDER IMPLICATIONS OF THE FINDINGS: Since 17BIPHE2 also exerted bactericidal activity against N. gonorrhoeae at its spermicidal concentration, it is a promising candidate to be developed into a vaginal multipurpose prevention technology agent, thus empowering women against unplanned pregnancies and sexually transmitted infections. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Canadian Institutes of Health Research (PJT 173268 to N.T.). There are no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Lee SG, Kiattiburut W, Khongkha T, et al. 17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeae. Hum Reprod. 2022. PMID: 36053257. doi:10.1093/humrep/deac188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。